|Slideshows|September 23, 2021

Are You Ready for the Annual Psychiatric Times World CME Conference?

At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Using AI to Write Psychiatric Progress Notes

ByDinah Miller, MD

November 18th 2025

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

ByBrian Miller, MD, PhD, MPH

November 17th 2025

FDA Clears Deep Transcranial Magnetic Stimulation for Adolescents With MDD

ByLeah Kuntz

November 14th 2025

Lamotrigine: An Update on Its Role in Bipolar Disorder

ByDavid N. Osser, MD

November 14th 2025

schizophrenia cobenfy data analysis inpatient

Post-Hoc Analysis of Predictive Factors for Response to Adjunctive Cobenfy

ByJessica Walters

November 14th 2025

Latest CME

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Are You Ready for the Annual Psychiatric Times World CME Conference?

Newsletter

Related Content

Using AI to Write Psychiatric Progress Notes

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

FDA Clears Deep Transcranial Magnetic Stimulation for Adolescents With MDD

Lamotrigine: An Update on Its Role in Bipolar Disorder

Post-Hoc Analysis of Predictive Factors for Response to Adjunctive Cobenfy

Latest CME

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

ADHD: Correcting Careless Myths

Toward a Spiritual Psychiatry Subspecialty

Lecanemab or Lithium for Alzheimer Disease Dementia? New Data Change Everything

Tonmya Available Commercially for Treatment of Fibromyalgia

Planned FDA Investigational New Drug Application: SPC-15 for the Treatment of PTSD